New nasal spray could ease public speaking panic in social anxiety
NCT ID NCT06615557
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 38 times
Summary
This study tests an investigational nasal spray (fasedienol) for quickly reducing anxiety during a public speaking challenge in adults aged 18–65 with social anxiety disorder. Participants receive either the spray or a placebo and rate their distress levels. The goal is to see if the spray provides fast symptom relief without long-term treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER (SAD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vistagen Clinical Site
Phoenix, Arizona, 85012, United States
-
Vistagen Clinical Site
Little Rock, Arkansas, 72211, United States
-
Vistagen Clinical Site
Bellflower, California, 90706, United States
-
Vistagen Clinical Site
Oceanside, California, 92056, United States
-
Vistagen Clinical Site
Orange, California, 92868, United States
-
Vistagen Clinical Site
Redlands, California, 92374, United States
-
Vistagen Clinical Site
Torrance, California, 90504, United States
-
Vistagen Clinical Site
Denver, Colorado, 80209, United States
-
Vistagen Clinical Site
Tampa, Florida, 33629, United States
-
Vistagen Clinical Site
Decatur, Georgia, 30030, United States
-
Vistagen Clinical Site
Chicago, Illinois, 60640, United States
-
Vistagen Clinical Site
Naperville, Illinois, 60563, United States
-
Vistagen Clinical Site
Boston, Massachusetts, 02131, United States
-
Vistagen Clinical Site
Bloomfield Township, Michigan, 48302, United States
-
Vistagen Clinical Site
Flowood, Mississippi, 39232, United States
-
Vistagen Clinical Site
Las Vegas, Nevada, 89119, United States
-
Vistagen Clinical Site
Las Vegas, Nevada, 89121, United States
-
Vistagen Clinical Site
Albuquerque, New Mexico, 87109, United States
-
Vistagen Clinical Site
New York, New York, 10128, United States
-
Vistagen Clinical Site
Cincinnati, Ohio, 45229, United States
-
Vistagen Clinical Site
Austin, Texas, 78737, United States
-
Vistagen Clinical Site
Austin, Texas, 78759, United States
-
Vistagen Clinical Site
Dallas, Texas, 75251, United States
-
Vistagen Clinical Site
Houston, Texas, 77055, United States
-
Vistagen Clinical Site
San Antonio, Texas, 78229, United States
-
Vistagen Clinical Site
Everett, Washington, 98201, United States
Conditions
Explore the condition pages connected to this study.